DENVER – Trained technician screeners with assisted computer-aided nodule detection or computer vision (CV) screening workstations can efficiently and accurately review and triage abnormal low-dose computed topography (LDCT) scans for radiologist review.
DENVER – A cross-sectional survey showed a quarter of patients with detected incidental pulmonary nodules experienced significant distress related to the nodule. Detailed clinician communication increased patient knowledge, relieved distress, and improved patient experience.
DENVER – Metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR) identified unique metabolic biomarkers specific to lung cancer patients and allowed for the accurate identification of a cohort of patients with early and late-stage lung cancer.
FDA-Approved ALK IHC CDx is Superior to Another IHC Assay for Patient Selection of ALK Inhibitor Treatment
DENVER – The U.S. Food and Drug Administration (FDA) approved VENTANA anti-ALK(D5F3)CDx performed more accurately than another commonly used immunohistochemistry (IHC) assay, based on the use of the 5A4 clone, for the selection of patients eligible to receive ALK tyrosine kinase inhibitor (TKI) treatment.
DENVER – Preliminary research has identified autoantibodies, immune proteins found in the blood specific for one’s own proteins, that can potentially detect lung cancer early by distinguishing between smokers with or without lung cancer and also discriminate between lung cancer and low-dose computed tomography (LDCT) detected non-cancerous lung lesions.
DENVER – Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI) afatinib compared to standard platinum doublet chemotherapy.